Overview For the vaccination of healthy, susceptible horses 6 months of age or older, including pregnant mares, as an aid in the reduction of respiratory disease due to equine herpesvirus type 1 (EHV-1) and type 4 (EVH-4) and by equine influenza type A2 virus.

Benefits:
  • Incorporates the latest emerging North American EIV strain (Ohio/2003), as well as an established North American EIV strain (Kentucky/2/95)
  • Also incorporates a relevant Eurasian EIV strain (Newmarket/2/93)
  • Unique EHV-1 equine respiratory origin isolate
  • Minimal vaccine site reactions
  • Three dose regiment conforms to AAEP recommendations
  • Safe, all killed vaccine